US EditionPublished • loading... • Updated
Researchers try bold new approach in a race to better treat autoimmune diseases
Researchers at Johns Hopkins and NIH use CAR-T and mRNA nanoparticle therapies to reprogram immune systems, aiming for precise treatments in early clinical trials involving autoimmune diseases.
- Researchers at Johns Hopkins University are developing immune reprogramming therapies, with work led by Sachin Surwase, who studies autoimmune diseases in the lab, on November 13, 2025.
- Because current therapies suppress rather than fix the cause, patients with autoimmune diseases often face lifelong, costly pills or infusions while CAR-T therapy remains expensive and limited.
- CAR-T therapy harvests and reprograms T cells after chemotherapy, mRNA packaged in biodegradable nanoparticles instruct immune 'generals', and T-cell engager drugs like teclistamab redirect T cells to target B cells.
- In early clinical reports, a single infusion produced remission in a German patient who has stayed off medicines since March 2021, while most patients improved and six entered drug-free remission, clinical meeting reports show.
- Many strategies will require more years of testing and safety data, and CAR-T research programs are furthest along but face questions about safety and benefit duration in treating a broad cohort of autoimmune diseases.
Insights by Ground AI
28 Articles
28 Articles
PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
A peek inside some leading research labs shows how scientists-turned-detectives are painstakingly decoding what causes autoimmune diseases and how to stop the immune system from attacking you instead of protecting you.
·United States
Read Full Article
Scientists create special antibody that shuts down rogue T cells safely
A promising breakthrough in autoimmune disease research may open the door to safer and more effective treatments. Scientists have engineered a special antibody that can selectively calm the immune system without weakening its defenses. Their method targets the specific immune cells that cause damage in diseases like Type 1 diabetes, hepatitis, and multiple sclerosis—without the usual side effects of widespread immune suppression. The research, p…
Coverage Details
Total News Sources28
Leaning Left9Leaning Right0Center14Last UpdatedBias Distribution61% Center
Bias Distribution
- 61% of the sources are Center
61% Center
L 39%
C 61%
Factuality
To view factuality data please Upgrade to Premium
